Log in

Relevant bibliographies by topics / IL-6 / Journal articles

To see the other types of publications on this topic, follow the link: IL-6.

Journal articles on the topic 'IL-6'

Author: Grafiati

Published: 4 June 2021

Last updated: 25 May 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'IL-6.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Toshiro, Shimamura, Taki Shinsuke, Honda Hideo, Yokota Masataka, Ito Satoru, and Takahara Yoshiyuki. "Analysis of interleukin 6 (IL-6)/IL-6 receptor system using monoclonal anti-IL-6 antibodies." Molecular Immunology 28, no. 11 (November 1991): 1155–61. http://dx.doi.org/10.1016/0161-5890(91)90001-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

TAMM, IGOR. "IL-6." Annals of the New York Academy of Sciences 557, no. 1 (June 28, 2008): 478–89. http://dx.doi.org/10.1111/j.1749-6632.1989.tb24040.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Gaillard, O. "Interleukine 6 (IL-6)." Immuno-analyse & Biologie Spécialisée 17, no. 3 (June 2002): 140–42. http://dx.doi.org/10.1016/s0923-2532(02)01191-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Matsuda, Tadashi, and Toshio Hirano. "Interleukin 6 (IL-6)." Biotherapy 2, no. 4 (October 1990): 363–73. http://dx.doi.org/10.1007/bf02170085.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Hansen, MB, M. Svenson, M. Diamant, C. Ross, and K. Bendtzen. "Interleukin-6 (IL-6) autoantibodies and blood IL-6 measurements [letter]." Blood 85, no. 4 (February 15, 1995): 1145. http://dx.doi.org/10.1182/blood.v85.4.1145.bloodjournal8541145.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Usha, Prof. "IL-4 and IL-6 in Bronchial Asthma Does IL-6 Plays More Important Role than IL-4? A Preliminary Study." Journal of Medical Science And clinical Research 05, no. 04 (April 18, 2017): 20446–50. http://dx.doi.org/10.18535/jmscr/v5i4.115.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Van Wagoner, Nicholas J., Jae-Wook Oh, Pavle Repovic, and Etty N. Benveniste. "Interleukin-6 (IL-6) Production by Astrocytes: Autocrine Regulation by IL-6 and the Soluble IL-6 Receptor." Journal of Neuroscience 19, no. 13 (July 1, 1999): 5236–44. http://dx.doi.org/10.1523/jneurosci.19-13-05236.1999.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Baran, Paul, Rebecca Nitz, Joachim Grötzinger, Jürgen Scheller, and Christoph Garbers. "Minimal Interleukin 6 (IL-6) Receptor Stalk Composition for IL-6 Receptor Shedding and IL-6 Classic Signaling." Journal of Biological Chemistry 288, no. 21 (April 5, 2013): 14756–68. http://dx.doi.org/10.1074/jbc.m113.466169.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Jostock, Thomas, Guido Blinn, Christoph Renné, Karl-Josef Kallen, Stefan Rose-John, and Jürgen Müllberg. "Immunoadhesins of interleukin-6 and the IL-6/soluble IL-6R fusion protein hyper-IL-6." Journal of Immunological Methods 223, no. 2 (March 1999): 171–83. http://dx.doi.org/10.1016/s0022-1759(98)00218-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Pooran, Nakechand, Anant Indaram, Pankaj Singh, and Simmy Bank. "Cytokines (IL-6, IL-8, TNF)." Journal of Clinical Gastroenterology 37, no. 3 (September 2003): 263–66. http://dx.doi.org/10.1097/00004836-200309000-00013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Nishimoto, Norihiro. "6. IL-6 Inhibitors for Treatment of Rheumatoid Arthritis." Nihon Naika Gakkai Zasshi 97, no. 10 (2008): 2413–17. http://dx.doi.org/10.2169/naika.97.2413.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

SNICK, JACQUES, JEAN-CHRISTOPHE RENAULD, RICHARD J. SIMPSON, CATHERINE UYTTENHOVE, and ANNE VINK. "Mouse IL-6." Annals of the New York Academy of Sciences 557, no. 1 (June 28, 2008): 206–14. http://dx.doi.org/10.1111/j.1749-6632.1989.tb24014.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Hodgson, John. "Patenting IL-6." Nature Biotechnology 10, no. 1 (January 1992): 16. http://dx.doi.org/10.1038/nbt0192-16.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

McInnes, Iain. "Considering IL-6." Considerations in Medicine 2, no. 1 (November 2018): 1. http://dx.doi.org/10.1136/conmed-2018-000006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Metz, Silke, Monique Wiesinger, Michael Vogt, Heike Lauks, Günther Schmalzing, Peter C. Heinrich, and Gerhard Müller-Newen. "Characterization of the Interleukin (IL)-6 Inhibitor IL-6-RFP." Journal of Biological Chemistry 282, no. 2 (November 3, 2006): 1238–48. http://dx.doi.org/10.1074/jbc.m606885200.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

De Benedetti, F., M. Massa, P. Pignatti, S. Albani, D. Novick, and A. Martini. "Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis." Journal of Clinical Investigation 93, no. 5 (May 1, 1994): 2114–19. http://dx.doi.org/10.1172/jci117206.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Nakajima, Ayako. "2. IL-6 Inhibitor." Nihon Naika Gakkai Zasshi 100, no. 10 (2011): 2972–78. http://dx.doi.org/10.2169/naika.100.2972.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Szot, Patricia, Allyn Franklin, Dianne P. Figlewicz, Timothy Petru Beuca, Kristin Bullock, Kim Hansen, William A. Banks, Murray A. Raskind, and Elaine R. Peskind. "Multiple lipopolysaccharide (LPS) injections alter interleukin 6 (IL-6), IL-7, IL-10 and IL-6 and IL-7 receptor mRNA in CNS and spleen." Neuroscience 355 (July 2017): 9–21. http://dx.doi.org/10.1016/j.neuroscience.2017.04.028.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Baran, Paul, Selina Hansen, Georg H. Waetzig, Mohammad Akbarzadeh, Larissa Lamertz, Heinrich J. Huber, M. Reza Ahmadian, Jens M. Moll, and Jürgen Scheller. "The balance of interleukin (IL)-6, IL-6·soluble IL-6 receptor (sIL-6R), and IL-6·sIL-6R·sgp130 complexes allows simultaneous classic and trans-signaling." Journal of Biological Chemistry 293, no. 18 (March 20, 2018): 6762–75. http://dx.doi.org/10.1074/jbc.ra117.001163.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Uchiyama, Yasushi, Hiroto Yoshida, Nobuo Koike, Naohiko Hayakawa, Atsuko Sugita, Takashi Nishimura, and Masahiko Mihara. "Anti-IL-6 receptor antibody increases blood IL-6 level via the blockade of IL-6 clearance, but not via the induction of IL-6 production." International Immunopharmacology 8, no. 11 (November 2008): 1595–601. http://dx.doi.org/10.1016/j.intimp.2008.07.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

HIRANO, TOSHIO. "Interleukin 6 (IL-6) and disease." Japanese Journal of Clinical Immunology 13, no. 5 (1990): 444–45. http://dx.doi.org/10.2177/jsci.13.444.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Schöbitz, Bernd, Gita Pezeshki, Thomas Pohl, Ulrike Hemmann, Peter C. Heinrich, Florian Holsboer, and Johannes M. H. M. Reul. "Soluble interleukin‐6 (IL‐6) receptor augments central effects of IL‐6 in vivo." FASEB Journal 9, no. 8 (May 1995): 659–64. http://dx.doi.org/10.1096/fasebj.9.8.7768358.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Hansen, Morten Bagge, Morten Svenson, Kathrine Abell, Kiyoshi Yasukawa, Marcus Diamant, and Klaus Bendtzen. "Influence of interleukin-6 (IL-6) autoantibodies on IL-6 binding to cellular receptors." European Journal of Immunology 25, no. 2 (February 1995): 348–54. http://dx.doi.org/10.1002/eji.1830250207.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Baiocchi, Marta, Isabella Marcucci, Stefan Rose-John, Ottaviano Serlupi-Crescenzi, and Mauro Biffoni. "AN IL-6/IL-6 SOLUBLE RECEPTOR (IL-6R) HYBRID PROTEIN (H-IL-6) INDUCES EPO-INDEPENDENT ERYTHROID DIFFERENTIATION IN HUMAN CD34+CELLS." Cytokine 12, no. 9 (September 2000): 1395–99. http://dx.doi.org/10.1006/cyto.2000.0723.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Rose-John, Stefan. "IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6." International Journal of Biological Sciences 8, no. 9 (2012): 1237–47. http://dx.doi.org/10.7150/ijbs.4989.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Suzuki, H., H. Takemura, K. Yoshizaki, Y. Koishihara, Y. Ohsugi, A. Okano, Y. Akiyama, T. Tojo, T. Kishimoto, and H. Kashiwagi. "IL-6-anti-IL-6 autoantibody complexes with IL-6 activity in sera from some patients with systemic sclerosis." Journal of Immunology 152, no. 2 (January 15, 1994): 935–42. http://dx.doi.org/10.4049/jimmunol.152.2.935.

Full text

Abstract:

Abstract Anti-IL-6 IgG autoantibodies, often found in sera from patients with systemic sclerosis, may increase to the level sufficient to bind significant amounts of IL-6 in serum. In our study of the role of anti-IL-6 autoantibodies in serum, we found that some sera with the autoantibodies possessed considerably higher IL-6 levels (more than 100 pg/ml) compared with most of sera without the autoantibodies. Size-exclusion HPLC of the sera with these autoantibodies demonstrated that a significant part of the serum IL-6 activity was attributable to circulating IL-6-anti-IL-6 autoantibody complexes. Gel filtration of IL-6-anti-IL-6 IgG complexes made in vitro by incubation of rIL-6 and IgG purified from the autoantibody-positive sera demonstrated that the complexes at 200 to 250 kDa were dominant ones and that IL-6 bound to the autoantibodies retained more than 60% of the original IL-6 activity. Moreover, IL-6-anti-IL-6 autoantibody complexes were shown to bind to recombinant soluble IL-6 receptors. Estimated affinity of anti-IL-6 IgG autoantibodies from two patients was fairly high (4.2 x 10(9) to 3.3 x 10(10) L/M). Therefore, the retention of IL-6 activity by IL-6-anti-IL-6 autoantibody complexes may be explained by intact receptor-binding sites on the autoantibody-bound IL-6 molecules. Taken together, these results suggest that the properties of anti-IL-6 autoantibodies are consistent with a potential role as specific carriers for IL-6 in the circulation.

APA, Harvard, Vancouver, ISO, and other styles

27

Park, Sung Tae. "상대적 운동 강도가 형철 IL-2, IL-6 농도에 미치는 효과." Journal of Sport and Leisure Studies 23 (May 31, 2005): 319–27. http://dx.doi.org/10.51979/kssls.2005.05.23.319.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Tanaka, Toshio, Masashi Narazaki, and Tadamitsu Kishimoto. "Interleukin (IL-6) Immunotherapy." Cold Spring Harbor Perspectives in Biology 10, no. 8 (August 4, 2017): a028456. http://dx.doi.org/10.1101/cshperspect.a028456.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Hoene, Miriam, Louise Fritsche, Rainer Lehmann, Anita M. Hennige, Hans-Ulrich Häring, Erwin Schleicher, and Cora Weigert. "Running without IL-6." Medicine & Science in Sports & Exercise 40, Supplement (May 2008): S192. http://dx.doi.org/10.1249/01.mss.0000322290.16416.c4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Rose-John, Stefan, and Markus F. Neurath. "IL-6 trans-Signaling." Immunity 20, no. 1 (January 2004): 2–4. http://dx.doi.org/10.1016/s1074-7613(04)00003-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Gutierrez, G., G. Junovich, V. Dubinsky, and T. Gentile. "IL-6 in reproduction." Journal of Reproductive Immunology 75, no. 1 (August 2007): A4—A5. http://dx.doi.org/10.1016/j.jri.2007.06.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Upadhyaya, Smitha, Vinitha Kadamkode, Rafi Mahammed, Chandraprabha Doraiswami, and Gautam Banerjee. "Adiponectin and IL-6." Adipocyte 3, no. 1 (October 8, 2013): 39–45. http://dx.doi.org/10.4161/adip.26553.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Malberg, Kurt. "Psychostress und IL-6." Allergo Journal 20, no. 3 (April 2011): 134. http://dx.doi.org/10.1007/bf03362453.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Pizzi, Marina, Ilenia Sarnico, Flora Boroni, Marina Benarese, Michel Dreano, Gianni Garotta, Alessandra Valerio, and PierFranco Spano. "Prevention of neuron and oligodendrocyte degeneration by interleukin-6 (IL-6) and IL-6 receptor/IL-6 fusion protein in organotypic hippocampal slices." Molecular and Cellular Neuroscience 25, no. 2 (February 2004): 301–11. http://dx.doi.org/10.1016/j.mcn.2003.10.022.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Ding, W., L. L. Stohl, V. Isak, J. A. Wagner, Z. Bulmer, and R. D. Granstein. "006 IL-6 enhances IL-6 expression by epidermal langerhans cells (LCs)." Journal of Investigative Dermatology 142, no. 8 (August 2022): S1. http://dx.doi.org/10.1016/j.jid.2022.05.060.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Potere, Nicola, Alberto Batticciotto, Alessandra Vecchié, Ettore Porreca, Antonella Cappelli, Antonio Abbate, Francesco Dentali, and Aldo Bonaventura. "The role of IL-6 and IL-6 blockade in COVID-19." Expert Review of Clinical Immunology 17, no. 6 (May 27, 2021): 601–18. http://dx.doi.org/10.1080/1744666x.2021.1919086.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Müllberg, Jürgen, Till Geib, Thomas Jostock, Susanne H. Hoischen, Petra Vollmer, Nicole Voltz, David Heinz, Peter R. Galle, Mariam Klouche, and Stefan Rose-John. "IL-6 Receptor Independent Stimulation of Human gp130 by Viral IL-6." Journal of Immunology 164, no. 9 (May 1, 2000): 4672–77. http://dx.doi.org/10.4049/jimmunol.164.9.4672.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Nanki, Toshihiro. "Advances of treatment with IL-6/IL-6 receptor inhibitors for RA." Proceedings for Annual Meeting of The Japanese Pharmacological Society WCP2018 (2018): SY61–2. http://dx.doi.org/10.1254/jpssuppl.wcp2018.0_sy61-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Suzuki, H., K. Yasukawa, T. Saito, M. Anzai, R. Goitsuka, A. Hasegawa, Y. Ohsugi, T. Taga, and T. Kishimoto. "Anti-murine IL-6 receptor antibody inhibits IL-6 effects in vivo." Immunology Letters 30, no. 1 (September 1991): 17–22. http://dx.doi.org/10.1016/0165-2478(91)90083-m.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Li, Yan, Carl-Magnus Bäckesjö, Lars-Arne Haldosén, and Urban Lindgren. "IL-6 receptor expression and IL-6 effects change during osteoblast differentiation." Cytokine 43, no. 2 (August 2008): 165–73. http://dx.doi.org/10.1016/j.cyto.2008.05.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Osborne, Julie, Patrick S. Moore, and Yuan Chang. "KSHV-encoded viral IL-6 activates multiple human IL-6 signaling pathways." Human Immunology 60, no. 10 (October 1999): 921–27. http://dx.doi.org/10.1016/s0198-8859(99)00083-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Gadient, R. A., and U. Otten. "Postnatal expression of interleukin-6 (IL-6) and IL-6 receptor (IL-6R) mRNAs in rat sympathetic and sensory ganglia." Brain Research 724, no. 1 (June 1996): 41–46. http://dx.doi.org/10.1016/0006-8993(96)00264-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Gadient, R. A., A. Lachmund, K. Unsicker, and U. Otten. "Expression of interleukin-6 (IL-6) and IL-6 receptor mRNAs in rat adrenal medulla." Neuroscience Letters 194, no. 1-2 (July 1995): 17–20. http://dx.doi.org/10.1016/0304-3940(95)11708-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Hoyland, Judith A., A. J. Freemont, and P. T. Sharpe. "Interleukin-6, IL-6 receptor, and IL-6 nuclear factor gene expression in paget's disease." Journal of Bone and Mineral Research 9, no. 1 (December 3, 2009): 75–80. http://dx.doi.org/10.1002/jbmr.5650090111.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Berndt, J. D. "IL-11 Trumps IL-6 in Gastrointestinal Cancer." Science Signaling 6, no. 291 (September 3, 2013): ec208-ec208. http://dx.doi.org/10.1126/scisignal.2004692.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Sabite;KARATAN, KAÇAR. "AMİLOİDOZİSDE SERUM IL-6, IL-1a, TNFa DÜZEYLERİ." Ankara Üniversitesi Tıp Fakültesi Mecmuası 52, no. 4 (1999): 1. http://dx.doi.org/10.1501/tipfak_0000000401.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Brunssen, Susan H., Sheryl S. Moy, Arrel D. Toews, Christopher A. McPherson, and G. Jean Harry. "Interleukin-6 (IL-6) receptor/IL-6 fusion protein (Hyper IL-6) effects on the neonatal mouse brain: Possible role for IL-6 trans-signaling in brain development and functional neurobehavioral outcomes." Brain, Behavior, and Immunity 27 (January 2013): 42–53. http://dx.doi.org/10.1016/j.bbi.2012.08.017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Inoue, K., H. Sugiyama, H. Ogawa, T. Yamagami, T. Azuma, Y. Oka, H. Miwa, K. Kita, A. Hiraoka, and T. Masaoka. "Expression of the interleukin-6 (IL-6), IL-6 receptor, and gp130 genes in acute leukemia." Blood 84, no. 8 (October 15, 1994): 2672–80. http://dx.doi.org/10.1182/blood.v84.8.2672.2672.

Full text

Abstract:

Abstract Expression patterns of interleukin-6 (IL-6), IL-6 receptor (IL-6R), and gp130 genes in 39 patients with acute myeloid leukemia (AML), in 23 patients with acute lymphoblastic leukemia (ALL), and in 7 patients with acute mixed lineage leukemia (AMLL) were studied by quantitative reverse transcriptase-polymerase chain reaction. Significant levels of IL-6 were expressed in 8 (21%) of 39 AML patients and in 2 (29%) of 7 AMLL patients, whereas in ALL, the expression of IL-6 was almost negligible. IL-6R was expressed in all patients with AML and AMLL, whereas only half of ALL patients expressed low levels of IL-6R as compared with those with AML and AMLL. However, gp130 was ubiquitously expressed in all the leukemia patients, and there was no significant difference in gp130 expression among AML, ALL, and AMLL. Significant correlation was observed between the expression of IL-6R and gp130 in AML. When tested for in vitro response to IL-6, the leukemic cells from 3 of 7 AML, none of 3 ALL, and both of 2 AMLL patients significantly responded to IL-6, showing the correlation between the expression levels of IL-6R and gp130 and the responsiveness of leukemic cells to IL-6. These results showed that quantitation of IL-6R and gp130 expression by reverse transcriptase-polymerase chain reaction is useful for the rapid prediction of the responsiveness of leukemic cells to IL- 6, especially in cases of administration of IL-6.

APA, Harvard, Vancouver, ISO, and other styles

49

Inoue, K., H. Sugiyama, H. Ogawa, T. Yamagami, T. Azuma, Y. Oka, H. Miwa, K. Kita, A. Hiraoka, and T. Masaoka. "Expression of the interleukin-6 (IL-6), IL-6 receptor, and gp130 genes in acute leukemia." Blood 84, no. 8 (October 15, 1994): 2672–80. http://dx.doi.org/10.1182/blood.v84.8.2672.bloodjournal8482672.

Full text

Abstract:

Expression patterns of interleukin-6 (IL-6), IL-6 receptor (IL-6R), and gp130 genes in 39 patients with acute myeloid leukemia (AML), in 23 patients with acute lymphoblastic leukemia (ALL), and in 7 patients with acute mixed lineage leukemia (AMLL) were studied by quantitative reverse transcriptase-polymerase chain reaction. Significant levels of IL-6 were expressed in 8 (21%) of 39 AML patients and in 2 (29%) of 7 AMLL patients, whereas in ALL, the expression of IL-6 was almost negligible. IL-6R was expressed in all patients with AML and AMLL, whereas only half of ALL patients expressed low levels of IL-6R as compared with those with AML and AMLL. However, gp130 was ubiquitously expressed in all the leukemia patients, and there was no significant difference in gp130 expression among AML, ALL, and AMLL. Significant correlation was observed between the expression of IL-6R and gp130 in AML. When tested for in vitro response to IL-6, the leukemic cells from 3 of 7 AML, none of 3 ALL, and both of 2 AMLL patients significantly responded to IL-6, showing the correlation between the expression levels of IL-6R and gp130 and the responsiveness of leukemic cells to IL-6. These results showed that quantitation of IL-6R and gp130 expression by reverse transcriptase-polymerase chain reaction is useful for the rapid prediction of the responsiveness of leukemic cells to IL- 6, especially in cases of administration of IL-6.

APA, Harvard, Vancouver, ISO, and other styles

50

Nemunaitis, J., DF Andrews, DY Mochizuki, MB Lilly, and JW Singer. "Human marrow stromal cells: response to interleukin-6 (IL-6) and control of IL-6 expression." Blood 74, no. 6 (November 1, 1989): 1929–35. http://dx.doi.org/10.1182/blood.v74.6.1929.1929.

Full text

Abstract:

Abstract Production of interleukin-6 (IL-6) by marrow stromal cells from human long-term marrow cultures and from stromal cells transformed with simian virus 40 was examined. As with other cultured mesenchymal cells, unstimulated stromal cells produced undetectable amounts of IL-6 mRNA when assayed by Northern blots. However, within 30 minutes after exposure of transformed marrow stromal cells to the inflammatory mediators, recombinant human interleukin-1 alpha (IL-1 alpha) or recombinant human tumor necrosis factor alpha (TNF alpha), significant increases in IL-6 expression were observed. The time course of IL-6 mRNA upregulation in transformed marrow stromal cells with IL-1 alpha and TNF alpha differed: The maximal response to TNF alpha was observed at 30 minutes whereas that to IL-1 alpha occurred at 8 hours. Although IL-6 at a concentration of 500 U/mL was inhibitory to adherent transformed marrow stromal cell proliferation, a concentration- dependent stimulation of anchorage-independent colony growth was observed when the cells were plated in semisolid medium with IL-6. The stromal cell colony-stimulating effect of IL-6 was abrogated by a neutralizing antibody to IL-6. Moreover, the heteroserum with anti-IL-6 activity and two anti-IL-6 monoclonal antibodies partially blocked autonomous and IL-1 alpha-induced colony formation, suggesting that colony formation by transformed marrow stromal cells may require IL-6. Clonal-transformed stromal cell lines were derived from the anchorage- independent stromal cell colonies. Both IL-6 mRNA and protein were constitutively produced at high levels. The addition of IL-6 to either long-term marrow culture adherent cells or transformed marrow stromal cells downregulated the expression of collagen I, a major stromal cell matrix protein. Thus, IL-6 affects proliferation of stromal cells and influences their production of extracellular matrix, suggesting that IL- 6 may have indirect as well as direct influences on hematopoietic cell proliferation.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!